Idexx Laboratories Stock Performance
| IDXX Stock | USD 421.76 4.44 1.06% |
The company retains a Market Volatility (i.e., Beta) of 1.02, which attests to a somewhat significant risk relative to the market. IDEXX Laboratories returns are very sensitive to returns on the market. As the market goes up or down, IDEXX Laboratories is expected to follow. At this point, IDEXX Laboratories has a negative expected return of -0.21%. Please make sure to check out IDEXX Laboratories' maximum drawdown, as well as the relationship between the daily balance of power and relative strength index , to decide if IDEXX Laboratories performance from the past will be repeated in the future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days IDEXX Laboratories has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 1.02 | Five Day Return 0.28 | Year To Date Return (23.02) | Ten Year Return 464.57 | All Time Return 44.5 K |
Last Split Factor 2:1 | Last Split Date 2015-06-16 |
1 | Disposition of 500 shares by Szostak M Anne of IDEXX Laboratories at 469.3723 subject to Rule 16b-3 | 09/06/2024 |
2 | IDEXX Laboratories Inc s Winning Formula Financial Metrics and Competitive Strengths | 09/10/2024 |
3 | Idexx Sees Q3 Revenue Boost | 10/31/2024 |
4 | 1000 Invested In This Stock 10 Years Ago Would Be Worth 5,600 Today | 11/04/2024 |
5 | A Once-in-a-Decade Opportunity 1 Super SP 500 Stock Down 40 percent to Buy After Its Recent Pullback | 11/05/2024 |
6 | Is It Time to Buy Octobers Worst-Performing Nasdaq Stocks | 11/06/2024 |
7 | Peregrine Asset Advisers Inc. Cuts Stake in IDEXX Laboratories, Inc. | 11/11/2024 |
8 | Axxcess Wealth Management LLC Reduces Stock Holdings in IDEXX Laboratories, Inc. | 11/12/2024 |
9 | At US420, Is It Time To Put IDEXX Laboratories, Inc. On Your Watch List | 11/19/2024 |
10 | IDEXX Laboratories Announces CFO Transition | 11/21/2024 |
11 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 3,382 Shares of IDEXX Laboratories, Inc. | 11/22/2024 |
| Begin Period Cash Flow | 112.5 M |
IDEXX |
IDEXX Laboratories Relative Risk vs. Return Landscape
If you would invest 48,728 in IDEXX Laboratories on August 29, 2024 and sell it today you would lose (6,552) from holding IDEXX Laboratories or give up 13.45% of portfolio value over 90 days. IDEXX Laboratories is currently does not generate positive expected returns and assumes 1.8104% risk (volatility on return distribution) over the 90 days horizon. In different words, 16% of stocks are less volatile than IDEXX, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
IDEXX Laboratories Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for IDEXX Laboratories' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as IDEXX Laboratories, and traders can use it to determine the average amount a IDEXX Laboratories' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1153
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IDXX |
Estimated Market Risk
| 1.81 actual daily | 16 84% of assets are more volatile |
Expected Return
| -0.21 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average IDEXX Laboratories is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of IDEXX Laboratories by adding IDEXX Laboratories to a well-diversified portfolio.
IDEXX Laboratories Fundamentals Growth
IDEXX Stock prices reflect investors' perceptions of the future prospects and financial health of IDEXX Laboratories, and IDEXX Laboratories fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on IDEXX Stock performance.
| Return On Equity | 0.59 | ||||
| Return On Asset | 0.23 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.37 % | ||||
| Current Valuation | 34.86 B | ||||
| Shares Outstanding | 81.88 M | ||||
| Price To Earning | 61.31 X | ||||
| Price To Book | 21.12 X | ||||
| Price To Sales | 8.89 X | ||||
| Revenue | 3.66 B | ||||
| Gross Profit | 2 B | ||||
| EBITDA | 1.1 B | ||||
| Net Income | 845.04 M | ||||
| Cash And Equivalents | 114.36 M | ||||
| Cash Per Share | 1.37 X | ||||
| Total Debt | 1.07 B | ||||
| Debt To Equity | 3.27 % | ||||
| Current Ratio | 0.89 X | ||||
| Book Value Per Share | 19.72 X | ||||
| Cash Flow From Operations | 906.51 M | ||||
| Earnings Per Share | 10.35 X | ||||
| Market Capitalization | 34.17 B | ||||
| Total Asset | 3.26 B | ||||
| Retained Earnings | 4.44 B | ||||
| Working Capital | 543.71 M | ||||
| Current Asset | 821.63 M | ||||
| Current Liabilities | 856.76 M | ||||
About IDEXX Laboratories Performance
Evaluating IDEXX Laboratories' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if IDEXX Laboratories has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if IDEXX Laboratories has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 94.36 | 120.45 | |
| Return On Tangible Assets | 0.30 | 0.32 | |
| Return On Capital Employed | 0.48 | 0.26 | |
| Return On Assets | 0.26 | 0.27 | |
| Return On Equity | 0.57 | 0.60 |
Things to note about IDEXX Laboratories performance evaluation
Checking the ongoing alerts about IDEXX Laboratories for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for IDEXX Laboratories help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| IDEXX Laboratories generated a negative expected return over the last 90 days | |
| IDEXX Laboratories is unlikely to experience financial distress in the next 2 years | |
| IDEXX Laboratories currently holds 1.07 B in liabilities with Debt to Equity (D/E) ratio of 3.28, implying the company greatly relies on financing operations through barrowing. IDEXX Laboratories has a current ratio of 0.87, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about IDEXX Laboratories' use of debt, we should always consider it together with its cash and equity. | |
| Over 94.0% of IDEXX Laboratories shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: BNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 3,382 Shares of IDEXX Laboratories, Inc. |
- Analyzing IDEXX Laboratories' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether IDEXX Laboratories' stock is overvalued or undervalued compared to its peers.
- Examining IDEXX Laboratories' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating IDEXX Laboratories' management team can have a significant impact on its success or failure. Reviewing the track record and experience of IDEXX Laboratories' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of IDEXX Laboratories' stock. These opinions can provide insight into IDEXX Laboratories' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for IDEXX Stock Analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.